What is William Blair's Forecast for SLDB Q1 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings per share estimates for shares of Solid Biosciences in a research report issued on Friday, May 16th. William Blair analyst S. Corwin expects that the company will post earnings per share of ($0.54) for the quarter. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. William Blair also issued estimates for Solid Biosciences' Q2 2026 earnings at ($0.54) EPS.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.06).

Other research analysts have also issued reports about the company. HC Wainwright upped their price target on Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a research report on Monday, March 10th. JPMorgan Chase & Co. dropped their price target on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating on the stock in a research report on Thursday, March 13th. Chardan Capital dropped their price target on Solid Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Barclays dropped their price target on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating on the stock in a research report on Friday, May 16th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Thursday. Ten analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, Solid Biosciences has an average rating of "Buy" and an average price target of $14.90.

Solid Biosciences Trading Down 2.8%

Shares of Solid Biosciences stock traded down $0.08 on Monday, reaching $2.81. 871,960 shares of the company were exchanged, compared to its average volume of 1,076,039. The firm has a market capitalization of $217.82 million, a price-to-earnings ratio of -0.92 and a beta of 2.32. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $10.37. The stock has a fifty day moving average price of $3.28 and a 200-day moving average price of $4.10.

Institutional Trading of Solid Biosciences

Several hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP bought a new stake in Solid Biosciences during the 1st quarter valued at approximately $2,338,000. Goldman Sachs Group Inc. boosted its stake in Solid Biosciences by 32.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company's stock valued at $667,000 after purchasing an additional 43,910 shares during the period. EcoR1 Capital LLC bought a new stake in Solid Biosciences during the 1st quarter valued at approximately $2,754,000. Bain Capital Life Sciences Investors LLC boosted its stake in Solid Biosciences by 96.1% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock valued at $29,273,000 after purchasing an additional 3,877,087 shares during the period. Finally, AQR Capital Management LLC bought a new stake in Solid Biosciences during the 1st quarter valued at approximately $418,000. Institutional investors own 81.46% of the company's stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.